SC
BMRN icon

Savant Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Savant Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,936
Closed -$1.9M – 1125
2024
Q4 		$1.9M Buy
28,936
+14,930
+107% +$1M 0.02% 456
2024
Q3 		$984K Buy
+14,006
New +$1.17M 0.01% 651

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Savant Capital's BMRN Position: Q1 2025 in Review

Savant Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 28,936 shares — an estimated $1.9M sold.

Savant Capital first reported a position in BMRN in Q3 2024 and held it in 2 quarters. The position peaked at $1.9M in Q4 2024. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Savant Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Savant Capital sold 28,936 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $1.9M.
  • Savant Capital first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Savant Capital's BioMarin Pharmaceuticals position peaked at $1.9M in Q4 2024.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.